edited by John C. Somberg, monthly, $150 (institutions), $110 (individuals), New York, NY, Chapman & Hall, June, 1994—.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The American Journal of Therapeutics announces its scope as "providing a systematic approach to covering new advances in therapeutics, as well as considering issues in clinical pharmacology, drug development, methodology of drug evaluation or comparative aspects of pharmaceutical evaluation within a given class." The journal also aims to place advances in pharmacotherapy into "clinical perspective" and frame these advances in a "pharmacoeconomic context."
Based upon the seven issues reviewed, the journal has yet to achieve its desired goals. The editors claim to feature original articles on therapeutics with section reviews on topics such as regulatory affairs. In contrast, most of the original work published to date addresses bioavailability or pharmacokinetic studies with minimal attention to pharmacoeconomics. While the overall quality of the studies can be considered satisfactory, we
McCloskey WW, Pascarelli AM. American Journal of Therapeutics. JAMA. 1996;276(6):504-505. doi:10.1001/jama.1996.03540060080044